Overestimating the Benefit of Cancer Drugs-Reply

Affiliations

¹ London School of Economics and Political Science, London, England
² Institute of Global Health Innovation, Imperial College London, London, England

Comment

Sebastian Salas-Vega et al. JAMA Oncol. 2017.

. 2017 Dec 1;3(12):1738-1739.

doi: 10.1001/jamaoncol.2017.1976.

¹ London School of Economics and Political Science, London, England
² Institute of Global Health Innovation, Imperial College London, London, England

No abstract available

Comment on

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines.
Salas-Vega S, Iliopoulos O, Mossialos E. Salas-Vega S, et al. JAMA Oncol. 2017 Mar 1;3(3):382-390. doi: 10.1001/jamaoncol.2016.4166. JAMA Oncol. 2017. PMID: 28033447
Overestimating the Benefit of Cancer Drugs.
Prasad V. Prasad V. JAMA Oncol. 2017 Dec 1;3(12):1737-1738. doi: 10.1001/jamaoncol.2017.0107. JAMA Oncol. 2017. PMID: 28715568 No abstract available.